If you have been reading about Pro-Gly-Pro and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
== C == Cadiot–Chodkiewicz coupling Cadogan-Sundberg indole synthesis Camps quinoline synthesis Cannizzaro reaction Carbohydrate acetalisation Carbonyl reduction Carbonylation Carbylamine reaction Carroll reaction Castro–Stephens coupling Catalytic reforming Catellani Reaction Corey–Itsuno reduction (AKA Corey–Bakshi–Shibata reduction or CBS reduction) Chan–Lam coupling Chapman rearrangement Cheletropic reaction Chichibabin pyridine synthesis Chichibabin reaction Chiral pool synthesis Chugaev elimination (also transliterated as Tschugajeff reaction) Ciamician–Dennstedt rearrangement Claisen condensation Claisen rearrangement Claisen–Schmidt condensation Clemmensen reduction Collins reagent Combes quinoline synthesis Conia reaction Conrad–Limpach synthesis Cook–Heilbron thiazole synthesis Cope elimination Cope rearrangement Corey reagent Corey–Fuchs reaction Corey–Gilman–Ganem oxidation Corey–Kim oxidation Corey-Nicolaou macrolactonization Corey–Posner, Whitesides–House reaction Corey-Seebach reaction Corey–Winter olefin synthesis Corey–Winter reaction Cornforth rearrangement Coupling reaction Crabbé reaction Craig method Cram's rule of asymmetric induction Creighton process Criegee reaction Criegee rearrangement Cross metathesis Crum Brown–Gibson rule Curtius degradation Curtius rearrangement, Curtius reaction Cyanohydrin reaction
== Medical uses == Phenibut is used in Russia, Ukraine, Belarus and Latvia as a pharmaceutical drug to treat anxiety and to improve sleep (e.g., in the treatment of insomnia). It is also used for various other indications, including the treatment of asthenia, depression, alcoholism, alcohol withdrawal syndrome, post-traumatic stress disorder, stuttering, tics, vestibular disorders, Ménière's disease, dizziness, for the prevention of motion sickness, and for the prevention of anxiety before or after surgical procedures or painful diagnostic tests.
During his early years in the Senate, Biden focused on consumer protection and environmental issues and called for greater government accountability. In 1974, he described himself as liberal on civil rights and liberties, senior citizens' concerns, and healthcare, but conservative on other issues, including abortion and military conscription. Biden was the first U.S. senator to endorse Governor Jimmy Carter for president in the 1976 Democratic primary. Carter won the Democratic nomination and the 1976 election. Biden also worked on arms control. After Congress failed to ratify the SALT II Treaty signed in 1979 by Soviet general secretary Leonid Brezhnev and President Carter, Biden met with Soviet foreign minister Andrei Gromyko and secured changes that addressed the Senate Foreign Relations Committee's objections. He received considerable attention when he excoriated Secretary of State George Shultz at a Senate hearing for the Reagan administration's support of South Africa despite its policy of apartheid. In a congressional hearing in 1984, he objected to the Strategic Defense Initiative plan to construct autonomous systems of ICBM defense. Biden was an advocate for Delaware military installations, including Dover Air Force Base and New Castle Air National Guard Base. In the mid-1970s, Biden was one of the Senate's strongest opponents of race-integration busing. His Delaware constituents strongly opposed it, and such opposition nationwide later led his party to mostly abandon school integration policies.
Sources: en.wikipedia.org
Moore KL (2003). "The biology and enzymology of protein tyrosine O-sulfation". J. Biol. Chem. 278 (27): 24243–6. doi:10.1074/jbc.R300008200. PMID 12730193. Hoffhines AJ; Damoc, E; Bridges, KG; Leary, JA; Moore, KL (2006). "Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody". J. Biol. Chem. 281 (49): 37877–87. doi:10.1074/jbc.M609398200. PMC 1764208. PMID 17046811.
Food and Drug Administration (FDA) does not approve bromide for the treatment of any disease, and sodium bromide was removed from over-the-counter (OTC) sedative products like Bromo-Seltzer, in 1975. FDA banned organic bromides from OTC sleep aids in 1989. Commercially available organobromine pharmaceuticals include the vasodilator nicergoline, the sedative brotizolam, the anticancer agent pipobroman, and the antiseptic merbromin. Otherwise, organobromine compounds are rarely pharmaceutically useful, in contrast to the situation for organofluorine compounds. Several drugs are produced as the bromide (or equivalents, hydrobromide) salts, but in such cases bromide serves as an innocuous counterion of no biological significance. Organobromine compounds are used as psychedelic and designer drugs such as 2C-B, Bromo-DragonFLY, and 4-Bromomethcathinone. Other uses of organobromine compounds include high-density drilling fluids, dyes (such as Tyrian purple and the indicator bromothymol blue), and pharmaceuticals. Bromine itself, as well as some of its compounds, are used in water treatment, and is the precursor of a variety of inorganic compounds with an enormous number of applications (e.g. silver bromide for photography). Zinc–bromine batteries are hybrid flow batteries used for stationary electrical power backup and storage; from household scale to industrial scale. Bromine is used in cooling towers (in place of chlorine) for controlling bacteria, algae, fungi, and zebra mussels.
=== Pharmacodynamics === Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors. It is selective for the β1-adrenergic receptor and has intrinsic sympathomimetic activity. Carteolol has also been found to act as a serotonin 5-HT1A and 5-HT1B receptor antagonist in addition to being a beta blocker.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.